Octreotide: A Literature Course on What the Published Research Reports

Octreotide is a synthetic octapeptide — a chain of eight amino acids — built as a more stable analogue of the naturally occurring hormone somatostatin. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or treatment decision. The six modules below summarise what published papers reported, in the populations and models those papers used. Nothing here is a protocol, a regimen, or a statement about what any individual should expect.

Doses are deliberately omitted throughout. Where a specific quantity could not be verified against the papers cited on this page, it is left out rather than paraphrased.

Module 1: What Octreotide Is and How It Has Been Studied

Definition and class

Octreotide belongs to the somatostatin analogue class. Native somatostatin is a short-lived regulatory peptide; octreotide was engineered as a longer-lasting peptide that retains affinity for somatostatin receptors, and a 2023 delivery-focused review described octreotide as a somatostatin receptor–targeting peptide used both as a drug in its own right and as a targeting ligand attached to nanocarriers and other constructs (PMID 37211679).

Where it appears in the literature

The largest body of clinical writing concerns acromegaly. A review of octreotide for acromegaly summarised how the compound has been studied for the control of growth hormone–driven disease and how long-acting formulations changed the way it was administered in that setting (PMID 30754185). Beyond endocrinology, researchers have published a translational trial of octreotide and human lymphatic fluid transport (PMID 37951584), a rodent study of neuroprotective, anticonvulsant and anxiolytic endpoints in Wistar rats (PMID 37499770), an experimental report on octreotide in direct and indirect lung injury (PMID 40933598), and a retrospective veterinary series of 18 dogs treated for protein-losing enteropathy (PMID 38038236).

Forms studied

Octreotide has been studied as an injectable peptide and as the payload of engineered release systems. Researchers reported on octreotide loaded into silk fibroin microspheres and on how formulation variables changed the release profile in laboratory testing (PMID 31147054), and a separate group reported on subcutaneously administered self-cleaving hydrogel–octreotide conjugates designed to provide very long-acting octreotide exposure (PMID 27253622). A population pharmacokinetic analysis examined an octreotide depot, CAM2029, in acromegaly (PMID 40418492). Radiolabelled octreotide has also appeared in imaging literature, including a report of octreotide uptake in a parathyroid adenoma (PMID 23487397).

Limits of the evidence in Module 1

The literature summarised here is heterogeneous: reviews, a translational trial, rodent experiments, a veterinary retrospective, formulation science and a single case report do not combine into one coherent evidence base. The presence of octreotide in a study is not evidence that the compound is appropriate outside the population that study enrolled.

Module 2: Mechanism as Described in the Literature

Somatostatin receptor binding

The mechanistic account consistently begins with somatostatin receptors. The 2023 delivery review described octreotide's affinity for somatostatin receptors as the property exploited when the peptide is used to direct carriers toward receptor-expressing tissue (PMID 37211679). The same receptor affinity underlies imaging applications, and a case report described octreotide uptake visualised in a parathyroid adenoma, consistent with receptor-mediated localisation (PMID 23487397).

Hormonal suppression

In endocrine disease, the described mechanism is inhibitory. The acromegaly review framed octreotide as a somatostatin analogue used because somatostatin signalling suppresses growth hormone secretion, and it discussed how that pharmacology has been applied clinically (PMID 30754185). A pharmacoepidemiologic study of infants with hyperinsulinism reflects the same inhibitory logic applied to insulin secretion (PMID 27910218).

Other proposed actions in preclinical work

Preclinical papers have proposed actions beyond hormone suppression. The Wistar rat study examined neuroprotective, anticonvulsant and anxiolytic endpoints and reported findings in those behavioural and histological domains (PMID 37499770), while an experimental report examined octreotide in models of direct and indirect lung injury (PMID 40933598). In the vascular and lymphatic domain, a translational trial examined octreotide and human lymphatic fluid transport, which the authors reported as improved under the conditions studied (PMID 37951584).

Limits of the evidence in Module 2

Mechanistic description is not proof of clinical consequence. Receptor affinity explains why a molecule localises or suppresses secretion; it does not establish that any downstream endpoint improves, and mechanisms demonstrated in rodents or in vitro have not necessarily been confirmed in humans.

Module 3: Reported Outcomes by Study

The table below lists the model or population, the endpoints examined, and what each report described. No entry should be read as a promise of benefit.

Formulation outcomes

Two formulation papers reported non-clinical endpoints. Researchers reported control of octreotide release from silk fibroin microspheres, showing that release behaviour could be modulated by the carrier (PMID 31147054), and a bioconjugate chemistry study reported that subcutaneously administered self-cleaving hydrogel–octreotide conjugates provided very long-acting octreotide (PMID 27253622).

Limits of the evidence in Module 3

Single case reports describe one patient and cannot establish causation. Rodent and canine findings do not transfer automatically to humans. The lymphatic trial was a translational study with the sample size and endpoints its authors chose, and none of these reports were designed to answer questions about healthy individuals or non-medical use.

Module 4: Octreotide Side Effects: What Studies Report

Safety information in the verified literature comes mainly from studies that set out to characterise harms rather than benefits.

Paediatric safety surveillance

A pharmacoepidemiologic study examined octreotide use and safety in infants with hyperinsulinism, reporting on exposure patterns and adverse events in that vulnerable population, with serious gastrointestinal complications framed as an outcome of concern (PMID 27910218). That paper exists precisely because clinicians wanted systematic data on harm rather than anecdote.

Veterinary and clinical observation

The retrospective veterinary series of 18 dogs treated with octreotide for protein-losing enteropathy recorded clinical course and tolerability in those animals as part of its case review (PMID 38038236). In the human endocrine setting, the acromegaly review discussed tolerability alongside efficacy when describing how octreotide has been used in that indication (PMID 30754185). Long-term administration has also been described in a single case of refractory gastric ulcer bleeding, where the patient remained on octreotide over an extended period (PMID 37051262).

Limits of the evidence in Module 4

None of the papers cited here is a comprehensive adverse-event catalogue, and abstract-level reporting does not capture every event recorded in full manuscripts or in regulatory labelling. Safety signals identified in infants, in dogs, or in acromegaly populations do not describe the risk profile in any other group, and the absence of a reported event in a small series is not evidence that the event does not occur. Approved-product labelling remains the authoritative source of adverse-reaction information for licensed octreotide products.

Module 5: Pharmacokinetics Where Data Exist

Population modelling

The most detailed pharmacokinetic work in this verified set is a population pharmacokinetic analysis of an octreotide depot, CAM2029, in the treatment of acromegaly, in which researchers built a model of octreotide exposure over time in that patient population (PMID 40418492). Population models of this kind are used to describe how exposure varies between individuals and which covariates account for that variation.

Why long-acting forms were developed

Formulation research is itself pharmacokinetic evidence. The delivery-systems review described the rationale for engineering octreotide carriers, including the peptide's limited persistence in its unmodified form (PMID 37211679). Consistent with that rationale, researchers reported controlled release of octreotide from silk fibroin microspheres in laboratory testing (PMID 31147054), and a separate group reported that self-cleaving hydrogel–octreotide conjugates given subcutaneously produced very long-acting octreotide exposure (PMID 27253622). The acromegaly review likewise discussed long-acting administration as a practical development in that indication (PMID 30754185).

Limits of the evidence in Module 5

Pharmacokinetic parameters derived in acromegaly patients receiving a specific depot product do not generalise to other formulations, routes or populations. In vitro release curves describe carrier behaviour in a test system, not in a living body. No parameter reported in these papers describes what would happen with any unapproved or compounded preparation.

Module 6: Regulatory Status, Stated Factually

Approved products

Octreotide is a regulated prescription drug in the United States and many other jurisdictions, not an unapproved research chemical. Approved octreotide products have included an immediate-release subcutaneous injection, a long-acting intramuscular depot suspension, and an oral delayed-release capsule formulation. Prescribing information for these products is issued by the manufacturer and reviewed by the relevant regulator, and it — not the summaries on this page — governs indications, contraindications and dosing.

Investigational products

Not every octreotide formulation studied in the literature is an approved product. The population pharmacokinetic analysis described above concerned CAM2029, an octreotide depot evaluated in acromegaly (PMID 40418492), and the hydrogel-conjugate and microsphere systems were laboratory and preclinical constructs rather than marketed medicines (PMID 27253622, PMID 31147054).

Research-use-only material and compounding

Peptide material sold under "research use only" labelling is not a medicine: RUO products are not manufactured, tested or released to pharmaceutical standards, and the labelling restricts them to laboratory work. Separately, compounding pharmacies in the United States operate under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which limit which bulk substances may be compounded and under what circumstances; whether a given substance may be compounded depends on FDA lists and state pharmacy law. Veterinary use of octreotide, such as the canine protein-losing enteropathy series, occurred outside any species-specific approval and was reported as clinical experience (PMID 38038236). This section is general information and is not legal advice.

Limits of the evidence in Module 6

Regulatory status changes, differs by country, and does not map onto the research literature. A compound may be approved for one narrow indication while most published studies concern other models entirely, and approval of one formulation says nothing about the legality or quality of another.

What the Studies Did Not Test

Across the papers summarised here, several questions were never asked:

• Healthy people. The human work cited involved patients — acromegaly populations, an infant cohort, a translational lymphatic trial and a case report — not healthy volunteers seeking enhancement (PMID 30754185, PMID 37951584).
• Body composition, athletic or cosmetic endpoints. No cited study measured them.
• Long-term outcomes outside approved indications. The long-term human description available here is a single ulcer-bleeding case report (PMID 37051262).
• Cross-species translation. The rat neurological findings and lung-injury model results were reported in animals and were not replicated in humans in this set (PMID 37499770, PMID 40933598).
• Unregulated or compounded material. No study cited here evaluated the identity, purity or behaviour of non-pharmaceutical octreotide preparations.

Readers with clinical questions about octreotide should raise them with a licensed physician who can weigh the approved labelling and individual circumstances.

References

• Octreotide for acromegaly (Expert Review of Endocrinology & Metabolism, 2007)
• Neuroprotective, anticonvulsant and anxiolytic effects of octreotide in Wistar rats (Journal of Chemical Neuroanatomy, 2023)
• Control of octreotide release from silk fibroin microspheres (Materials Science & Engineering C, 2019)
• Octreotide use and safety in infants with hyperinsulinism (Pharmacoepidemiology and Drug Safety, 2017)
• Octreotide and octreotide-derived delivery systems (Journal of Drug Targeting, 2023)
• Octreotide improves human lymphatic fluid transport: a translational trial (European Journal of Cardio-Thoracic Surgery, 2024)
• Population pharmacokinetic analysis of an octreotide depot (CAM2029) in the treatment of acromegaly (Clinical Pharmacokinetics, 2025)
• Octreotide uptake in parathyroid adenoma (Molecular Imaging and Radionuclide Therapy, 2012)
• Octreotide and direct/indirect lung injury (Research in Pharmaceutical Sciences, 2025)
• Use of octreotide for the treatment of protein-losing enteropathy in dogs: retrospective study of 18 cases (Journal of Veterinary Internal Medicine, 2024)
• Subcutaneously administered self-cleaving hydrogel-octreotide conjugates provide very long-acting octreotide (Bioconjugate Chemistry, 2016)
• Refractory gastric ulcer bleeding responsive to long-term octreotide (SAGE Open Medical Case Reports, 2023)